110 related articles for article (PubMed ID: 14556934)
21. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction.
Schandalik R; Perucca E
Drugs Exp Clin Res; 1994; 20(1):37-42. PubMed ID: 7924893
[TBL] [Abstract][Full Text] [Related]
22. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
23. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016.
Carini R; Comoglio A; Albano E; Poli G
Biochem Pharmacol; 1992 May; 43(10):2111-5. PubMed ID: 1599497
[TBL] [Abstract][Full Text] [Related]
24. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
26. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F
Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
[TBL] [Abstract][Full Text] [Related]
27. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
28. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
29. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
31. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos).
Kidd P; Head K
Altern Med Rev; 2005 Sep; 10(3):193-203. PubMed ID: 16164374
[TBL] [Abstract][Full Text] [Related]
32. [Inhibitory effect of recombinant anti-angiogenic peptide of tumstatin on growth and metastasis of human ovarian cancer transplanted in nude mice].
Zhang GM; Sui LH; Jia T; Zhao YZ; Fu SB; Liu XH; Yu Y
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):170-3. PubMed ID: 18756929
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
Mu J; Abe Y; Tsutsui T; Yamamoto N; Tai XG; Niwa O; Tsujimura T; Sato B; Terano H; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1996 Sep; 87(9):963-71. PubMed ID: 8878460
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Xu L; Yoneda J; Herrera C; Wood J; Killion JJ; Fidler IJ
Int J Oncol; 2000 Mar; 16(3):445-54. PubMed ID: 10675474
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer.
Xu TM; Xin Y; Cui MH; Jiang X; Gu LP
Chin Med J (Engl); 2007 Apr; 120(7):584-8. PubMed ID: 17442207
[TBL] [Abstract][Full Text] [Related]
37. A water-soluble polysaccharide from the roots of Polygala tenuifolia suppresses ovarian tumor growth and angiogenesis in vivo.
Yao H; Cui P; Xu D; Liu Y; Tian Q; Zhang F
Int J Biol Macromol; 2018 Feb; 107(Pt A):713-718. PubMed ID: 28923567
[TBL] [Abstract][Full Text] [Related]
38. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
39. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.
Kohno T; Mizukami H; Suzuki M; Saga Y; Takei Y; Shimpo M; Matsushita T; Okada T; Hanazono Y; Kume A; Sato I; Ozawa K
Cancer Res; 2003 Aug; 63(16):5091-4. PubMed ID: 12941839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
